Recce Pharmaceuticals Management
Management criteria checks 3/4
Recce Pharmaceuticals' CEO is James Graham, appointed in Aug 2020, has a tenure of 4.17 years. total yearly compensation is A$834.51K, comprised of 62.8% salary and 37.2% bonuses, including company stock and options. directly owns 2.92% of the company’s shares, worth €2.18M. The average tenure of the management team and the board of directors is 4.1 years and 5.9 years respectively.
Key information
James Graham
Chief executive officer
AU$834.5k
Total compensation
| CEO salary percentage | 62.8% |
| CEO tenure | 4.2yrs |
| CEO ownership | 2.9% |
| Management average tenure | 4.1yrs |
| Board average tenure | 5.9yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2024 | AU$835k | AU$524k | -AU$18m |
| Mar 31 2024 | n/a | n/a | -AU$14m |
| Dec 31 2023 | n/a | n/a | -AU$11m |
| Sep 30 2023 | n/a | n/a | -AU$12m |
| Jun 30 2023 | AU$775k | AU$551k | -AU$13m |
| Mar 31 2023 | n/a | n/a | -AU$14m |
| Dec 31 2022 | n/a | n/a | -AU$15m |
| Sep 30 2022 | n/a | n/a | -AU$13m |
| Jun 30 2022 | AU$548k | AU$328k | -AU$11m |
| Mar 31 2022 | n/a | n/a | -AU$10m |
| Dec 31 2021 | n/a | n/a | -AU$8m |
| Sep 30 2021 | n/a | n/a | -AU$11m |
| Jun 30 2021 | AU$2m | AU$294k | -AU$14m |
| Mar 31 2021 | n/a | n/a | -AU$13m |
| Dec 31 2020 | n/a | n/a | -AU$13m |
| Sep 30 2020 | n/a | n/a | -AU$9m |
| Jun 30 2020 | AU$216k | AU$187k | -AU$4m |
| Mar 31 2020 | n/a | n/a | -AU$4m |
| Dec 31 2019 | n/a | n/a | -AU$3m |
| Sep 30 2019 | n/a | n/a | -AU$3m |
| Jun 30 2019 | AU$177k | AU$155k | -AU$3m |
| Mar 31 2019 | n/a | n/a | -AU$2m |
| Dec 31 2018 | n/a | n/a | -AU$2m |
| Sep 30 2018 | n/a | n/a | -AU$2m |
| Jun 30 2018 | AU$160k | AU$142k | -AU$2m |
Compensation vs Market: James's total compensation ($USD567.46K) is about average for companies of similar size in the German market ($USD501.82K).
Compensation vs Earnings: James's compensation has increased whilst the company is unprofitable.
CEO
James Graham
4.2yrs
Tenure
AU$834,509
Compensation
Mr. James Hamilton-Bray Graham, B.Com. (Entrepreneurship), GAICD, serves as Chief Executive Officer at Recce Pharmaceuticals Ltd since August 28, 2020 and also serves as Managing Director since 2020. He ha...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman of the Board | 6.5yrs | AU$380.55k | 0.13% A$ 98.8k | |
| CEO, MD & Executive Director | 4.2yrs | AU$834.51k | 2.92% A$ 2.2m | |
| Chief Scientific Director & Executive Director | 4.1yrs | AU$530.84k | 1.33% A$ 993.7k | |
| Principal Quality Chemist & Executive Director | no data | AU$318.53k | 0.13% A$ 97.1k | |
| Principal Engineer & Head of Manufacturing | no data | AU$564.01k | 0.040% A$ 29.7k | |
| Chief Medical Advisor & Independent Non Executive Director | no data | AU$75.00k | 0.055% A$ 40.9k | |
| Chief Financial Officer | 6.9yrs | no data | no data | |
| Head of Marketing | 4.8yrs | no data | no data | |
| Company Secretary | 2.1yrs | no data | no data |
4.1yrs
Average Tenure
Experienced Management: R9Q's management team is considered experienced (4.1 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman of the Board | 6.5yrs | AU$380.55k | 0.13% A$ 98.8k | |
| CEO, MD & Executive Director | 9.3yrs | AU$834.51k | 2.92% A$ 2.2m | |
| Chief Scientific Director & Executive Director | 9.3yrs | AU$530.84k | 1.33% A$ 993.7k | |
| Principal Quality Chemist & Executive Director | 5.3yrs | AU$318.53k | 0.13% A$ 97.1k | |
| Chief Medical Advisor & Independent Non Executive Director | 4.3yrs | AU$75.00k | 0.055% A$ 40.9k | |
| Non-Executive Director | 2.1yrs | AU$81.25k | 0.011% A$ 8.4k |
5.9yrs
Average Tenure
Experienced Board: R9Q's board of directors are considered experienced (5.9 years average tenure).